Market Overview

Benzinga's Top Upgrades

Share:
Benzinga's Top Upgrades
Related BMY
The Top 10 Value Stocks In The S&P 500
Key Takeaways From The J.P. Morgan Healthcare Conference
3 Things In Biotech You Should Learn Today: January 18, 2018 (Seeking Alpha)
Related GNRC
The 'Bomb Cyclone' Portfolio: Winners And Losers
11 Technical Levels Discussed On Wednesday's PreMarket Prep

Analysts at Morgan Stanley upgraded Bristol-Myers Squibb Company (NYSE: BMY) from “equal-weight” to “overweight.” The target price for Bristol-Myers Squibb has been raised from $45 to $60. Bristol-Myers Squibb's shares closed at $48.77 on Friday.

Analysts at Goldman Sachs upgraded Generac Holdings (NYSE: GNRC) from “sell” to “neutral.” The target price for Generac Holdings has been raised from $32 to $49. Generac's shares closed at $50.44 on Friday.

Guggenheim Securities upgraded FMC Technologies (NYSE: FTI) from “neutral” to “buy.” The target price for FMC Technologies is set to $60. FMC Technologies' shares closed at $51.13 on Friday.

Analysts at Bank of America upgraded Astrazeneca PLC (NYSE: AZN) from “underperform” to “neutral.” Astrazeneca's shares closed at $52.74 on Friday.

Latest Ratings for BMY

DateFirmActionFromTo
Oct 2017Credit SuisseMaintainsNeutral
Oct 2017Leerink SwannMaintainsOutperform
Oct 2017CitigroupMaintainsBuy

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: top upgradesUpgrades Analyst Ratings

 

Related Articles (AZN + BMY)

View Comments and Join the Discussion!